Abstract
After hysterectomy, HSIL and cancer of the vagina are rare; we propose a conservative approach to management of abnormal vaginal cytology and/or high-risk HPV tests. Supplemental digital content is available in the text. Objective Vaginal cancer is an uncommon cancer of the lower genital tract, and standardized screening is not recommended. Risk factors for vaginal cancer include a history of other lower genital tract neoplasia or cancer, smoking, immunosuppression, and exposure to diethylstilbestrol in utero. Although cervical cancer screening after total hysterectomy for benign disease is not recommended, many women inappropriately undergo vaginal cytology and/or human papillomavirus (HPV) tests, and clinicians are faced with managing their abnormal results. Our objectives were to review the literature on vaginal cytology and high-risk HPV (hrHPV) testing and to develop guidance for the management of abnormal vaginal screening tests. Materials and Methods An electronic search of the PubMed database through 2015 was performed. Articles describing vaginal cytology or vaginal hrHPV testing were reviewed, and diagnostic accuracy of these tests when available was noted. Results The available literature was too limited to develop evidence-based recommendations for managing abnormal vaginal cytology and hrHPV screening tests. However, the data did show that (1) the risk of vaginal cancer in women after hysterectomy is extremely low, justifying the recommendation against routine screening, and (2) in women for whom surveillance is recommended, e.g., women posttreatment for cervical precancer or cancer, hrHPV testing may be useful in identification of vaginal cancer precursors. Conclusions Vaginal cancer is rare, and asymptomatic low-risk women should not be screened. An algorithm based on expert opinion is proposed for managing women with abnormal vaginal test results.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 119-125 |
| Number of pages | 7 |
| Journal | Journal of Lower Genital Tract Disease |
| Volume | 20 |
| Issue number | 2 |
| DOIs | |
| State | Published - Apr 1 2016 |
Fingerprint
Keywords
- HPV
- vaginal cancer
- vaginal cytology
- VaIN
ASJC Scopus subject areas
- Obstetrics and Gynecology
Cite this
A common clinical dilemma : Management of abnormal vaginal cytology and human papillomavirus test results. / Khan, Michelle J.; Massad, L. Stewart; Kinney, Walter; Gold, Michael A.; Mayeaux, Ej; Darragh, Teresa M.; Castle, Philip E.; Chelmow, David; Lawson, Herschel W.; Huh, Warner K.
In: Journal of Lower Genital Tract Disease, Vol. 20, No. 2, 01.04.2016, p. 119-125.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - A common clinical dilemma
T2 - Management of abnormal vaginal cytology and human papillomavirus test results
AU - Khan, Michelle J.
AU - Massad, L. Stewart
AU - Kinney, Walter
AU - Gold, Michael A.
AU - Mayeaux, Ej
AU - Darragh, Teresa M.
AU - Castle, Philip E.
AU - Chelmow, David
AU - Lawson, Herschel W.
AU - Huh, Warner K.
PY - 2016/4/1
Y1 - 2016/4/1
N2 - After hysterectomy, HSIL and cancer of the vagina are rare; we propose a conservative approach to management of abnormal vaginal cytology and/or high-risk HPV tests. Supplemental digital content is available in the text. Objective Vaginal cancer is an uncommon cancer of the lower genital tract, and standardized screening is not recommended. Risk factors for vaginal cancer include a history of other lower genital tract neoplasia or cancer, smoking, immunosuppression, and exposure to diethylstilbestrol in utero. Although cervical cancer screening after total hysterectomy for benign disease is not recommended, many women inappropriately undergo vaginal cytology and/or human papillomavirus (HPV) tests, and clinicians are faced with managing their abnormal results. Our objectives were to review the literature on vaginal cytology and high-risk HPV (hrHPV) testing and to develop guidance for the management of abnormal vaginal screening tests. Materials and Methods An electronic search of the PubMed database through 2015 was performed. Articles describing vaginal cytology or vaginal hrHPV testing were reviewed, and diagnostic accuracy of these tests when available was noted. Results The available literature was too limited to develop evidence-based recommendations for managing abnormal vaginal cytology and hrHPV screening tests. However, the data did show that (1) the risk of vaginal cancer in women after hysterectomy is extremely low, justifying the recommendation against routine screening, and (2) in women for whom surveillance is recommended, e.g., women posttreatment for cervical precancer or cancer, hrHPV testing may be useful in identification of vaginal cancer precursors. Conclusions Vaginal cancer is rare, and asymptomatic low-risk women should not be screened. An algorithm based on expert opinion is proposed for managing women with abnormal vaginal test results.
AB - After hysterectomy, HSIL and cancer of the vagina are rare; we propose a conservative approach to management of abnormal vaginal cytology and/or high-risk HPV tests. Supplemental digital content is available in the text. Objective Vaginal cancer is an uncommon cancer of the lower genital tract, and standardized screening is not recommended. Risk factors for vaginal cancer include a history of other lower genital tract neoplasia or cancer, smoking, immunosuppression, and exposure to diethylstilbestrol in utero. Although cervical cancer screening after total hysterectomy for benign disease is not recommended, many women inappropriately undergo vaginal cytology and/or human papillomavirus (HPV) tests, and clinicians are faced with managing their abnormal results. Our objectives were to review the literature on vaginal cytology and high-risk HPV (hrHPV) testing and to develop guidance for the management of abnormal vaginal screening tests. Materials and Methods An electronic search of the PubMed database through 2015 was performed. Articles describing vaginal cytology or vaginal hrHPV testing were reviewed, and diagnostic accuracy of these tests when available was noted. Results The available literature was too limited to develop evidence-based recommendations for managing abnormal vaginal cytology and hrHPV screening tests. However, the data did show that (1) the risk of vaginal cancer in women after hysterectomy is extremely low, justifying the recommendation against routine screening, and (2) in women for whom surveillance is recommended, e.g., women posttreatment for cervical precancer or cancer, hrHPV testing may be useful in identification of vaginal cancer precursors. Conclusions Vaginal cancer is rare, and asymptomatic low-risk women should not be screened. An algorithm based on expert opinion is proposed for managing women with abnormal vaginal test results.
KW - HPV
KW - vaginal cancer
KW - vaginal cytology
KW - VaIN
UR - http://www.scopus.com/inward/record.url?scp=84959170920&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84959170920&partnerID=8YFLogxK
U2 - 10.1097/LGT.0000000000000185
DO - 10.1097/LGT.0000000000000185
M3 - Article
C2 - 26901279
AN - SCOPUS:84959170920
VL - 20
SP - 119
EP - 125
JO - Journal of Lower Genital Tract Disease
JF - Journal of Lower Genital Tract Disease
SN - 1089-2591
IS - 2
ER -